NCT03418038 2026-03-18
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
9 trialsNCT03458260 2026-03-10
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT04663347 2026-03-03
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT05364424 2025-12-01
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT05821088 2025-11-20
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT04665765 2025-09-03
Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02393157 2025-08-08
O-ICE
New York Medical College
Phase 2 Recruiting
NCT02329080 2025-07-08
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed
NCT04189952 2025-05-31
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
University of Miami
Phase 2 Terminated